Proton/Photon Rt - Benign Meningiomas(P92-13)
Launched by MASSACHUSETTS GENERAL HOSPITAL · Sep 22, 2016
Trial Information
Current as of June 09, 2025
Completed
Keywords
ClinConnect Summary
* After initial interview and physical examination, an immobilization device (head mask, neck support, back support, etc.) will be made for the participant. A treatment planning CT will be performed and a radiation treatment plan will be based on this CT scan.
* The radiation dose will usually be given once a day, five days per week. The radiation treatment will take between 7 and 8 1/2 weeks, including treatment planning.
* Treatment doses will vary, and the dose each participant will receive will be made on the basis of random assignment. Participants will either receive the usual dose of...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 or over
- • Histological documentation of benign meningioma
- • Documentation by imaging studies (CT and/ or MRI) or residual or recurrent intracranial tumor
- • Karnofsky performance status of ≥ 70
- • Study specific informed consent
- Exclusion Criteria:
- • Malignant meningiomas
- • Prior cranial irradiation, except treatment of localized skin cancer of the face or scalp
- • Patients having a concurrent primary cancer (except skin)
- • Patients having another cancer controlled \< 3 years
- • Pregnant patients
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Helen A Shih, MD
Principal Investigator
Massachusetts General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials